CA-SAMBANOVA-SYSTEMS
26.10.2021 15:02:06 CEST | Business Wire | Press release
SambaNova Systems , the company building the industry’s most advanced software, hardware and services to run AI applications, today announced that its AI membership program for the enterprise, ELEVAITE , is now open for applications. The program is designed to lead select cohorts of enterprises into the AI-enabled future leveraging SambaNova’s unmatched AI technology, solutions, expertise, and proven success while addressing the biggest challenges of starting and scaling an AI program.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20211026005330/en/
“The emergence of AI and its expected impact on the Global 2000 – akin to the impact of the internet – is upon us,” said Rodrigo Liang, co-founder and CEO of SambaNova. “For those with a desire to embrace the transformational power of AI, there are huge opportunities. With SambaNova ELEVAITE, enterprises will receive unmatched education and technical guidance that directly supports successful AI initiatives from conception to deployment, scalability, and ROI with market visibility for their technology leadership.”
Leaders across industries such as financial services, energy, manufacturing, healthcare, and more realize it is time to apply AI to their organization’s data resources. ELEVAITE is uniquely designed to accelerate selected cohort enterprises’ deployment of the most advanced and performant AI software, hardware, and services available for AI, machine learning, and deep learning.
As an ELEVAITE member, SambaNova teams will work with businesses to determine the most impactful AI technologies based on SambaNova’s experience and deep understanding of enterprise needs to deliver business impact. These include use cases for Natural Language Processing, Vision, and Recommendation.
“Enterprises well suited to participate in ELEVAITE are those that recognize the imperative to drive focus on new initiatives when looking to accelerate AI capabilities inside organizations,” said Marshall Choy, VP of Product at SambaNova. “Working together, ELEVAITE members and SambaNova will accelerate the deployment and scalability inside their enterprises.”
“ELEVAITE membership is designed to deliver unmatched education and awareness on a personal and cohort basis to accelerate enterprises’ transformation to an AI-Enabled organization,” said Amy Love, Chief Marketing Officer at SambaNova. “The program also furthers the market-leading standing of the selected companies by presenting them as leaders in their field.”
ELEVAITE members receive access to three categories of benefits:
- Unmatched Collaboration for Success: By providing customized scoping, implementation and scaling of AI solutions, SambaNova’s dedicated technical and account leads will be with you every step of the way.
- Institutionalized Skills and Knowledge : SambaNova founders, senior executives, board members, technologists, and industry luminaries will educate participating organizations to deliver the resources required to implement AI initiatives and develop new AI skills.
- ELEVAITED Visibility Driving Enterprise Value: With access to the SambaNova VisionAIres program, participants can increase the visibility of their AI initiatives, develop thought leadership and enhance their company’s reputation through media exposure.
ELEVAITE reduces the risk for enterprises and commits to scalable deployment by providing access to unique SambaNova resources and knowledge to ensure they are successful with AI. Members have access to SambaNova’s turnkey platform, including Dataflow-as-a-Service™, an extensible AI services platform, and DataScale®, an integrated software and hardware platform delivering unrivaled performance, accuracy, scale and ease of use built on SambaNova’s Systems Reconfigurable Dataflow Architecture™. This eliminates the need for massive data science staffing, significantly reducing the cost of investment.
To learn more, schedule an executive conversation or to apply for the program, visit sambanova.ai/elevaite . The selection process will occur this fall and the first cohort program will begin in January 2022.
About SambaNova Systems:
SambaNova Systems is an AI innovation company that empowers organizations to deploy best-in-class solutions for natural language processing, computer vision, recommendation systems, and AI for science with confidence. SambaNova's flagship offering, Dataflow-as-a-Service™, helps organizations rapidly deploy AI in days, unlocking new revenue and boosting operational efficiency. SambaNova's DataScale® is an integrated software and hardware system using Reconfigurable Dataflow Architecture™, along with open standards and user interfaces. Headquartered in Palo Alto, California, SambaNova Systems was founded in 2017 by industry luminaries and hardware and software design experts from Sun/Oracle and Stanford University. Investors include SoftBank Vision Fund 2, funds and accounts managed by BlackRock, Intel Capital, GV, Walden International, Temasek, GIC, Redline Capital, Atlantic Bridge Ventures, Celesta, and several others. For more information, please visit us at sambanova.ai or contact us at info@sambanova.ai . Follow SambaNova Systems on LinkedIn .
View source version on businesswire.com: https://www.businesswire.com/news/home/20211026005330/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
KATE Launches "KABUKE: Break Convention" Kabuki-Inspired International Campaign17.7.2026 09:00:00 CEST | Press release
Where “NO MORE RULES.” intersects with the Kabuku spirit. Inspired by Japanese aesthetics, KATE shares the value of shadow enhancing makeup and self‑expression with the world. Global cosmetics brand KATE launched “KABUKE: Break Convention,” a new international campaign drawing on elements of Kabuki, the traditional Japanese performing art. The campaign debuted on Wednesday, July 8, 2026. In this campaign, KATE’s shadow enhancing makeup—rooted in Japanese aesthetics—was paired with the Kabuki spirit inherited from traditional Kabuki theater to communicate the value of individuality and self‑expression through makeup on a global scale. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260708829427/en/ KATE international campaign “KABUKE: Break Convention” key visual. Dedicated website: https://www.kate-global.net/my/special/kate_kabuki/ Since its founding, KATE has championed the slogan “NO MORE RULES.,” offering makeup that defi
Meiji Seika Pharma: Results from the Global Phase III Trial (Integral-2) of Nacubactam, a Novel β-Lactamase Inhibitor, Highlighted in The Lancet Microbe’s Coverage of ESCMID Global Congress 202617.7.2026 03:00:00 CEST | Press release
Meiji Seika Pharma Co., Ltd. (Headquarters: Tokyo, President and Representative Director: Toshiaki Nagasato) today announced that results from the global Phase III trial (Integral-2) of nacubactam (Development Code: OP0595), a novel β-lactamase inhibitor, were highlighted in The Lancet Microbe’s coverage of ESCMID Global Congress 2026 (held in Munich, Germany). As highlighted in The Lancet Microbe’s coverage, the key findings presented by Meiji Seika Pharma at ESCMID Global Congress 2026 are as follows: The Integral-2 study (jRCT2031230076) is a global Phase III clinical trial that enrolled patients with complicated urinary tract infections, acute uncomplicated pyelonephritis, hospital-acquired bacterial pneumonia, ventilator-associated bacterial pneumonia, or complicated intra-abdominal infections caused by carbapenem-resistant Gram-negative bacteria (excluding Acinetobacter species). The study has achieved the prespecified study objectives. For the primary endpoint of overall treatme
Yoshihiro Shimamura Joins the Marché du Film’s “Investors Circle 2026” as an Invited Investor, Backing a New Feature Film17.7.2026 03:00:00 CEST | Press release
Shimamura Yoshihiro Film Production Co., Ltd. (Head office: Osaka, Japan; Representative Director: Yoshihiro Shimamura), a company active in film production and investment, today announced that Representative Director Yoshihiro Shimamura has decided to invest in an international feature film after being invited to the “Investors Circle 2026” — a distinction that reflects his standing as one of the field’s most highly regarded producers and investors. Hosted by the Marché du Film, the business arm of the Festival de Cannes and one of the world’s largest film markets, the Investors Circle is an invitation-only summit that connects a select group of private investors with high-end feature films during early-stage financing. Held in Cannes, France, May 16-17, 2026, it brings internationally acclaimed directors and producers together with investors around a curated slate of projects in development. During the summit, Shimamura attended private pitching sessions and, after individual meeting
Takeda’s Zasocitinib Demonstrates Consistent, High Rates of Skin Clearance Across the Body, Including Hard-to-Treat and High-Impact Sites, in Phase 3 Psoriasis Studies17.7.2026 00:00:00 CEST | Press release
On average, about 75% of patients with scalp psoriasis treated with zasocitinib achieved clear or almost clear skin at week 16 Approximately 70% of patients with palmoplantar disease treated with zasocitinib achieved clear or almost clear skin at week 16 Zasocitinib demonstrated statistically significant improvements in Nail Psoriasis Severity Index (NAPSI) versus placebo Results reinforce the potential of zasocitinib to deliver rapid and durable skin clearance, including in the hardest-to-treat areas, in a convenient once-daily pill Takeda (TSE:4502/NYSE:TAK) announced new data from the two pivotal Phase 3 studies of zasocitinib (TAK-279), a next-generation, highly selective and potent oral tyrosine kinase 2 (TYK2) inhibitor, in adults with moderate-to-severe plaque psoriasis (PsO).1 Presented at the 2026 American Academy of Dermatology (AAD) Innovation Academy, these secondary endpoint data show that zasocitinib demonstrated consistent and high rates of skin clearance across hard-to-
Merz Completes Inaugural €450 Million Schuldschein Loan Issuance16.7.2026 23:36:00 CEST | Press release
Debut transaction more than three times oversubscribed The Merz Group has successfully completed its first-ever Schuldschein loan issuance, placing a total volume of €450 million in the debt capital market – a multiple of three relating to the launch volume. The debut transaction was significantly oversubscribed and attracted strong interest from all investor groups. The proceeds were settled and paid out today. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260716926041/en/ Dr. Almuth Steinkühler, Chief Financial Officer Merz Group The transaction comprises both fixed- and floating-rate tranches with maturities of three, five, seven, and ten years. Around 50 German and international investors participated, representing a broad range of institutions, including private banks, German federal state-owned banks, public savings banks, cooperative banks, pension funds and occupational pension institutions. With the successful plac
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom